Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia

  • Kristine Doney
  • Kenneth Kopecky
  • Rainer Storb
  • C. Dean Buckner
  • Jack Singer
  • Claudio Anasetti
  • Fred Appelbaum
  • Patrick Beatty
  • William Bensinger
  • Ronald Berenson
  • Reginald Clift
  • H. Joachim Deeg
  • John Hansen
  • Roger Hill
  • Tom Loughran
  • Paul Martin
  • Finn Bo Petersen
  • George Sale
  • Jean Sanders
  • Keith Sullivan
  • Patricia Stewart
  • Paul Weiden
  • Robert Witherspoon
  • E. Donnall Thomas

Abstract

Treatment recommendations for aplastic anemia are based on long-term survival data for recipients of syngeneic or allogeneic bone marrow transplants (BMT) and the more recent results of “immunosuppressive therapy” (1ST), which usually includes antihuman thymocyte globulin (ATG) or antihuman lymphoblast globulin (ALG). Patient age and availability of a suitable marrow donor limit the number of patients who are potential candidates for marrow grafting. Many centers will not recommend an allogeneic BMT for patients with aplasia who are over 40 years of age, although some extend the upper age limit to 50 years. Suitable marrow donors include identical twins, genotypically HLA-identical siblings, or phenotypically HLA-identical family members. Transplants using HLA-mismatched family members or phenotypically identical, unrelated donors are usually reserved for “salvage” therapy after failure of a nontransplant treatment regimen.

Keywords

Hepatitis Europe Leukemia Corticosteroid Pneumonia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48:63–70.PubMedGoogle Scholar
  2. 2.
    Storb R, Deeg HJ, Whitehead J, et al. Marrow transplantation for leukemia and aplastic anemia: Two controlled trials of a combination of methotrexate and cyclosporine versus cyclosporine alone or methotrexate alone for prophylaxis of acute graft-versus-host disease. Trans Proc 1987; 19:2608–2613.Google Scholar
  3. 3.
    Doney K, Dahlberg SJ, Monroe D, et al. Therapy of severe aplastic anemia with anti-human thymocyte globulin and androgens: The effect of HLA-haploidentical marrow infusion. Blood 1984; 63:342–348.PubMedGoogle Scholar
  4. 4.
    Doney K, Storb R, Buckner CD, et al. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol 1987; 15:239–242.PubMedGoogle Scholar
  5. 5.
    Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. New Engl J Med 1975; 292:832–843, 895–902.PubMedCrossRefGoogle Scholar
  6. 6.
    Sullivan K, Witherspoon R, Storb R, et al. Chronic graft-versus-host disease: Pathogenesis, diagnosis, treatment, and prognostic factors. In: Baum SJ, Santos GW, Takaku F, eds. Recent Advances and Future Directions in Bone Marrow Transplantation. New York, Springer-Verlag, 1987: pp. 150–157.Google Scholar
  7. 7.
    Storb R, Thomas ED, Buckner CD, et al. Marrow transplantation in thirty “untransfused” patients with severe aplastic anemia. Ann Intern Med. 1980; 92:30–36.PubMedGoogle Scholar
  8. 8.
    Gluckman E for the Advisory Committee of the International Bone Marrow Transplant Registry. Current status of bone marrow transplantation for severe aplastic anemia: A preliminary report from the International Bone Marrow Transplant Registry. Trans Proc 1987; 19:2597–2599.Google Scholar
  9. 9.
    Speck B, Gratwohl A, Nissen C, et al. Treatment of aplastic anemia. Exp Hematol 1986; 14:126–132.Google Scholar
  10. 10.
    Bacigalupo A, Di Giorgio F, Congui M, et al. Treatment of severe aplastic anemia in Europe 1970–1983. A report of the EBMT working party. Exp Hematol 1985; 13:56–57 (Suppl 17) Google Scholar
  11. 11.
    Sullivan K, Deeg HJ, Sanders JE, et al. Late complications after marrow transplantation. Sem Hematol 1984; 21:53–63.Google Scholar
  12. 12.
    Witherspoon R, Fisher L, Sullivan K, et al. Secondary malignancies after human marrow transplantation. Exp Hematol 1988; 16:484 (abstract) Google Scholar
  13. 13.
    Nissen C, Gratwohl A, Speck B, et al. Acquired aplastic anemia: A PNH-like disease? Brit J Haematol 1986; 64:355–362.CrossRefGoogle Scholar
  14. 14.
    Marsh JCW, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987; 70:1046–1052.PubMedGoogle Scholar
  15. 15.
    Torok-Storb B, Doney K, Sale G, et al. Subsets of patients with aplastic anemia identified by flow microfluorometry. N Engl J Med 1985; 312:1015–1022.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Inc. 1990

Authors and Affiliations

  • Kristine Doney
  • Kenneth Kopecky
  • Rainer Storb
  • C. Dean Buckner
  • Jack Singer
  • Claudio Anasetti
  • Fred Appelbaum
  • Patrick Beatty
  • William Bensinger
  • Ronald Berenson
  • Reginald Clift
  • H. Joachim Deeg
  • John Hansen
  • Roger Hill
  • Tom Loughran
  • Paul Martin
  • Finn Bo Petersen
  • George Sale
  • Jean Sanders
  • Keith Sullivan
  • Patricia Stewart
  • Paul Weiden
  • Robert Witherspoon
  • E. Donnall Thomas

There are no affiliations available

Personalised recommendations